2016
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal Of Translational Medicine 2016, 14: 299. PMID: 27760559, PMCID: PMC5070187, DOI: 10.1186/s12967-016-1026-2.Peer-Reviewed Original ResearchConceptsMelanoma-specific survivalShorter melanoma-specific survivalHost immune responseImmune responseTCGA cohortAge groupsClinicopathologic featuresSurvival outcomesPatient cohortPrimary melanomaHost anti-tumor immune responseMelanoma diagnosisAnti-tumor immune responseMelanoma Cooperative GroupIndependent prognostic factorPopulation-based surveillanceEnd Results ProgramGreater prognostic impactMelanoma patient cohortTop upstream regulatorsYounger age groupsAge-related factorsBrisk TILsConclusionsOlder ageLymphocyte measurementsImmunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Human Pathology 2016, 57: 116-125. PMID: 27473267, PMCID: PMC5706446, DOI: 10.1016/j.humpath.2016.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCD3 ComplexDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLeukocyte Common AntigensLymphocytes, Tumor-InfiltratingMaleMelanomaNeoplasm GradingPhenotypeProportional Hazards ModelsSkin NeoplasmsTime FactorsTreatment OutcomeConceptsAbsent tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesBrisk tumor-infiltrating lymphocytesRecurrence-free survivalPrimary melanomaTIL gradeOverall survivalImmunologic heterogeneityPresence of TILsHost antitumor immune responseAntitumor immune responseImmune checkpoint regulatorsLymphocyte markers CD3T cell activation pathwaysEosin-stained sectionsGene expression profilesIndependent prognosticationLymphocyte compositionTIL countSurvival outcomesImproved prognosisPrognostic valueHistologic evaluationNonbriskImmune responseChapter 20 Management of Melanoma Therapy-Associated Toxicities
Weiss S, Kavecansky J, Pavlick A. Chapter 20 Management of Melanoma Therapy-Associated Toxicities. 2016, 299-319. DOI: 10.1016/b978-0-12-803508-5.00020-2.Peer-Reviewed Original ResearchSkin cancer-related deathsAntitumor immune responseUnique adverse eventsCancer-related deathPatient survival outcomesNew therapeutic strategiesQuality of lifeMelanoma driver mutationsChapter 20 ManagementAdverse eventsAdvanced melanomaSurvival outcomesImmune responseTherapeutic strategiesInitial approvalAggressive natureSkin cancerNew casesPatient safetyDriver mutationsMelanomaSignificant delayTherapyCliniciansVast majority
2015
Revisiting determinants of prognosis in cutaneous melanoma
Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer 2015, 121: 4108-4123. PMID: 26308244, PMCID: PMC4666819, DOI: 10.1002/cncr.29634.Peer-Reviewed Original ResearchConceptsDeterminants of prognosisCutaneous melanomaStaging systemCurrent staging modelsCurrent staging systemLymph node spreadPrimary tumor thicknessAmerican Joint CommitteeCancer (AJCC) staging systemPresence of ulcerationPrimary cutaneous melanomaUseful prognostic biomarkerMelanoma staging systemNew prognostic toolClinical surveillance strategiesAdjuvant therapyAdvanced diseaseDistant metastasisPatient selectionNode spreadSurvival outcomesTumor thicknessImmunologic markersPatient prognosisPatient outcomes